Hao Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hao Peng has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Ai‐Hua Lin
Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China
1 shared publicationCheng‐Long Huang
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, People's Republic of China
1 shared publicationGeyun You
1 shared publication- Hai-Yang Chen
Department of Radiation Oncology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
1 shared publication Hongwu He
1 shared publicationHong‐Wen Tan
Ji'an Central People's Hospital, Ji'an, People's Republic of China
1 shared publication
Latest Publications
- Open Access
- 27 September 2019
- Published by Wiley in Cancer Medicine
- Vol. 8 (16) , 6887-6893
Thyroid dose‐volume thresholds for the risk of radiation‐related hypothyroidism in nasopharyngeal carcinoma treated with intensity‐modulated radiotherapy—A single‐institution study
Background: To identify thyroid dose‐volume thresholds for radiotherapy (RT)‐related hypothyroidism (HT) in patients with nasopharyngeal carcinoma (NPC) treated with intensity‐modulated RT (IMRT). In this way, we desired to guide the design of treatment plans and, finally, lower HT prevalence.Methods: In total, 345 NPC patients treated with IMRT were evaluated retrospectively during a median follow‐up of 45.2 (range, 11.3‐64.9) months. Serum‐based assessments of thyroid function before and after IMRT were monitored periodically. Thyroid dose‐volume parameters were analyzed for their association with HT risk.Results: In total, 44.1% of patients (152/345) developed primary HT. Analyses of thyroid dose‐volume parameters identified a stringent dose‐volume histogram (DVH) threshold defined by V25Gy (the percentage thyroid volume that receives >25 Gy, not the absolute volume) ≤60%, V35Gy ≤ 55%, and V45Gy ≤ 45%. Patients whose thyroid DVHs satisfied these constraints had a lower prevalence of 2‐year HT compared with the overall prevalence (13.2% vs 25.8%, P < .001). Another DVH was defined by V25Gy > 95%, V35Gy > 90%, and V45Gy > 75%, and patients whose thyroid DVHs satisfied with these constraints had a higher prevalence of 2‐year HT than the overall incidence (36.0% vs 25.8%, P < .001).Conclusion: We recommend V25Gy ≤ 60%, V35Gy ≤ 55%, and V45Gy ≤ 45% as the “stringent” DVH line, and V25Gy > 95%, V35Gy > 90%, and V45Gy > 75% as the “inhibition” DVH line, under the precondition of not compromising the target coverage. These findings could help in the design of individual treatment plans and, eventually, to lowering of HT prevalence.
- 27 September 2019
- Published by Wiley in Cancer Medicine
- Vol. 8 (16) , 6887-6893
Open AccessThyroid dose‐volume thresholds for the risk of radiation‐related hypothyroidism in nasopharyngeal carcinoma treated with intensity‐modulated radiotherapy—A single‐institution study
Background: To identify thyroid dose‐volume thresholds for radiotherapy (RT)‐related hypothyroidism (HT) in patients with nasopharyngeal carcinoma (NPC) treated with intensity‐modulated RT (IMRT). In this way, we desired to guide the design of treatment plans and, finally, lower HT prevalence.Methods: In total, 345 NPC patients treated with IMRT were evaluated retrospectively during a median follow‐up of 45.2 (range, 11.3‐64.9) months. Serum‐based assessments of thyroid function before and after IMRT were monitored periodically. Thyroid dose‐volume parameters were analyzed for their association with HT risk.Results: In total, 44.1% of patients (152/345) developed primary HT. Analyses of thyroid dose‐volume parameters identified a stringent dose‐volume histogram (DVH) threshold defined by V25Gy (the percentage thyroid volume that receives >25 Gy, not the absolute volume) ≤60%, V35Gy ≤ 55%, and V45Gy ≤ 45%. Patients whose thyroid DVHs satisfied these constraints had a lower prevalence of 2‐year HT compared with the overall prevalence (13.2% vs 25.8%, P < .001). Another DVH was defined by V25Gy > 95%, V35Gy > 90%, and V45Gy > 75%, and patients whose thyroid DVHs satisfied with these constraints had a higher prevalence of 2‐year HT than the overall incidence (36.0% vs 25.8%, P < .001).Conclusion: We recommend V25Gy ≤ 60%, V35Gy ≤ 55%, and V45Gy ≤ 45% as the “stringent” DVH line, and V25Gy > 95%, V35Gy > 90%, and V45Gy > 75% as the “inhibition” DVH line, under the precondition of not compromising the target coverage. These findings could help in the design of individual treatment plans and, eventually, to lowering of HT prevalence.
- Open Access
- 1 January 2017
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 8 (3) , 417-424
Pretreatment Alkaline Phosphatase and Epstein-Barr Virus DNA Predict Poor Prognosis and Response to Salvage Radiotherapy in Patients with Nasopharyngeal Carcinoma and Metachronous Bone-Only Metastasis
Background: The bones are the most common site of distant metastasis in nasopharyngeal carcinoma (NPC). Few prognostic markers are available to guide treatment and sub-classify patients with bone metastasis. We aimed to identify the prognostic value of pretreatment serum alkaline phosphatase (ALP) and plasma Epstein-Barr virus DNA (EBV DNA) in patients with bone-only metastasis.
- 1 January 2017
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 8 (3) , 417-424
Open AccessPretreatment Alkaline Phosphatase and Epstein-Barr Virus DNA Predict Poor Prognosis and Response to Salvage Radiotherapy in Patients with Nasopharyngeal Carcinoma and Metachronous Bone-Only Metastasis
Background: The bones are the most common site of distant metastasis in nasopharyngeal carcinoma (NPC). Few prognostic markers are available to guide treatment and sub-classify patients with bone metastasis. We aimed to identify the prognostic value of pretreatment serum alkaline phosphatase (ALP) and plasma Epstein-Barr virus DNA (EBV DNA) in patients with bone-only metastasis.
- Open Access
- 1 September 2014
- Published by China Science Publishing & Media Ltd. in Chinese Journal of Applied Chemistry
- Vol. 31 (09) , 993
Research Progress on Synthesis and Application of Cyclotriphosphazene-based Flame Retardants
In this paper, the synthesis and reaction mechanism of hexachlorocyclotriphosphazene were briefly introduced. The flame-retardant mechanism of cyclotriphosphazene-based flame retardants was also summarized. The reactive-type hydroxyl, amino, epoxy, alkenyl, and carboxyl, cyclotriphosphazene and the additive-type alkoxy and aryloxy cyclotriphosphazene flame retardants were elaborated on their synthesis and application. The thermal stability and flame retardant properties of cyclotriphosphazene-based flame retardant materials were summarized. The development trend of cyclotriphosphazenebased flame retardants was also summarized and prospected.
- 1 September 2014
- Published by China Science Publishing & Media Ltd. in Chinese Journal of Applied Chemistry
- Vol. 31 (09) , 993
Open AccessResearch Progress on Synthesis and Application of Cyclotriphosphazene-based Flame Retardants
In this paper, the synthesis and reaction mechanism of hexachlorocyclotriphosphazene were briefly introduced. The flame-retardant mechanism of cyclotriphosphazene-based flame retardants was also summarized. The reactive-type hydroxyl, amino, epoxy, alkenyl, and carboxyl, cyclotriphosphazene and the additive-type alkoxy and aryloxy cyclotriphosphazene flame retardants were elaborated on their synthesis and application. The thermal stability and flame retardant properties of cyclotriphosphazene-based flame retardant materials were summarized. The development trend of cyclotriphosphazenebased flame retardants was also summarized and prospected.